BridgeBio Pharma (BBIO) | Stock Overview & Key Data
BridgeBio Pharma Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $84.94 on February 12, 2026
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
BridgeBio Pharma
BBIO
|
14.21B Large-cap | -5.68% | -7.41% | -2.47% | -10.61% | -18.35% | 93.46% | 364.66% | 14.32% | 145.68% | 145.68% | 145.68% |
|
Vertex
VRTX
|
109.45B Large-cap | -2.49% | -1.11% | -12.54% | -1.86% | -5.98% | 1.24% | 34.08% | 113.19% | 376.31% | 717.28% | 1,190.86% |
|
Regeneron
REGN
|
80.98B Large-cap | -5.03% | -15.02% | -23.79% | -18.77% | -22.36% | 25.39% | -16.92% | 20.10% | 53.41% | 959.24% | 4,557.42% |
|
Alnylam
ALNY
|
41.87B Large-cap | -3.17% | -3.96% | -11.98% | -38.46% | -28.50% | -0.85% | 55.93% | 107.40% | 330.17% | 2,975.15% | 1,859.64% |
|
Insmed
INSM
|
31.05B Large-cap | -4.72% | -25.91% | -29.11% | -49.79% | -41.44% | 53.32% | 447.13% | 322.07% | 796.14% | 920.13% | 585.32% |
|
Royalty Pharma plc
RPRX
|
29.43B Large-cap | 0.28% | 7.59% | 13.78% | 36.63% | 38.99% | 69.59% | 66.85% | 23.34% | 13.80% | 13.80% | 13.80% |
Ownership & Short Interest
Calculate Your BridgeBio Pharma Investment Returns
Long-Term Investment Performance Analysis
BridgeBio Pharma stock price in Jun 2019 was $26.97, A $1,000.00 lump sum investment in BridgeBio Pharma made 6 years ago would be worth approximately $2,427.88 today, representing a strong return of 142.79%. This translates to an annualized return (CAGR) of 13.63%.
6 Years 11 Months Investment Scenario (Jun 2019 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is BBIO's 52-week high and low?
- In the last 52 weeks, BridgeBio Pharma reached a high of $84.94 (on February 12, 2026) and a low of $35.15 (on N/A).
- What is the market cap and P/E ratio for BBIO?
- Curious about BridgeBio Pharma's size and valuation? Its market capitalization stands at 14.21B. When it comes to valuation, the P/E ratio (trailing twelve months) is -19.38, and the forward P/E (looking ahead) is 355.73.
- Does BBIO pay dividends? If so, what's the yield?
- As for dividends, BridgeBio Pharma isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are BridgeBio Pharma's main competitors or similar companies to consider before investing?
When looking at BridgeBio Pharma, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX109.45B Healthcare Biotechnology 1.24% 34.08% Regeneron
REGN80.98B Healthcare Biotechnology 25.39% -16.92% Alnylam
ALNY41.87B Healthcare Biotechnology -0.85% 55.93% Insmed
INSM31.05B Healthcare Biotechnology 53.32% 447.13% Royalty Pharma plc
RPRX29.43B Healthcare Biotechnology 69.59% 66.85% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for BridgeBio Pharma Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of BridgeBio Pharma's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 34.91%, the Debt to Equity ratio from the most recent quarter is -0.90, and its Gross Profit Margin stands at 94.74%.
- What is the recent revenue and earnings growth for BBIO?
- Looking at BridgeBio Pharma's growth, its revenue over the trailing twelve months (TTM) was $502M. Compared to the same quarter last year (YoY), quarterly revenue grew by 2,521.20%, and quarterly earnings saw a YoY growth of 2,521.18%.
- How much of BBIO stock is held by insiders and institutions?
- Wondering who owns BridgeBio Pharma stock? Company insiders (like executives and directors) hold about 4.28% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 100.73%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.